Table 1.
Case | Age* | Duration (years) | Trauma (years) | Career length | Neuropathology | A | B | C |
---|---|---|---|---|---|---|---|---|
CTE | ||||||||
A | 75 | 10 | 10/2 | 18 | CTE, ADNC, HS, TDP-43 | A3 | B2 | C1 |
B | 70 | 4 | 10/1 | 11 | CTE, ADNC, TDP-43 | A0 | B2 | C0 |
C | 60 | 6 | 1/1 | 26 | CTE, HS, TDP-43 | A0 | B1 | C0 |
D | 65 | 10 | – | 19 | CTE, ADNC, HS, TDP-43 | A2 | B2 | C1 |
E | 70 | 8 | 3/0 | 21 | CTE, TDP-43, PART, AGD | A0 | B1 | C0 |
F | 80 | 15 | F | 12 | CTE, ADNC, HS, TDP-43 | A2 | B2 | C0 |
G | 80 | 40 | – | 18 | CTE, ADNC, TDP-43 | A3 | B2 | C1 |
H | 70 | 11 | 50/1 | 17 | CTE/PART | A0 | B2 | C0 |
I | 70 | 9 | 10/1 | 19 | CTE, ADNC, TDP-43 | A2 | B1 | C1 |
J | 60 | 8 | 25/1 | 21 | CTE, ADNC, TDP-43 | A3 | B2 | C0 |
K | 70 | 26 | F | 20 | CTE | A0 | B2 | C0 |
ADNC | ||||||||
A | 90 | 5 | – | – | ADNC | A3 | B2 | C1 |
B | 70 | 3 | – | – | ADNC/TDP-43 | A2 | B2 | C1 |
C | 80 | 5 | – | – | ADNC/AGD | A0 | B1 | C0 |
D | 85 | 12 | – | – | ADNC/VD | A3 | B2 | C1 |
E | 90 | 9 | – | – | ADNC/TDP-43 | A2 | B1 | C1 |
F | 70 | 14 | – | – | ADNC | A1 | B2 | C1 |
G | 70 | 8 | – | – | ADNC | A3 | B2 | C1 |
Age rounded to nearest 5-year age interval to protect subject identities.
F, Frequent; ADNC, Alzheimer’s disease neuropathologic change; HS, Hippocampal sclerosis; TDP-43, Transactive response (TAR) DNA-binding protein of 43 kDa; PART, Primary age-related tauopathy; AGD, Argyrophilic grain disease; VD, Vascular disease.